White blood cell counts in six patients with chronic myeloid leukemia treated with the drug, STI571, which blocks the activity of the cancer-causing tyrosine kinase BCR-ABL. Each patient (denoted by a different colored line) received 500 mg of STI571 per day for 150 days. The dotted line represents the upper limit of the normal white blood cell count range.
Download the educator guide PDF, which includes questions to guide a class discussion on the graph characteristics and what the data show.
Figure 1 from:
Brian J. Druker, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. 2001. New England Journal of Medicine. 344(14): 1031-1037.
View Article
Date created:
02/01/2016
Date modified:
02/01/2016
